iRadimed Corporation (NASDAQ:IRMD) Announces Special Dividend of $0.50

iRadimed Corporation (NASDAQ:IRMD) announced a special dividend on Monday, December 8th. Shareholders of record on Wednesday, December 17th will be given a dividend of 0.50 per share by the medical equipment provider on Tuesday, December 30th. The ex-dividend date of this dividend is Wednesday, December 17th.

iRadimed has a dividend payout ratio of 34.2% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect iRadimed to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.68 annual dividend with an expected future payout ratio of 34.0%.

iRadimed Trading Up 1.0%

Shares of NASDAQ IRMD traded up $0.91 during midday trading on Monday, reaching $95.48. 71,897 shares of the stock were exchanged, compared to its average volume of 50,765. The stock has a 50 day moving average price of $81.57 and a 200-day moving average price of $70.16. The company has a market capitalization of $1.21 billion, a P/E ratio of 57.87 and a beta of 1.06. iRadimed has a 52-week low of $47.48 and a 52-week high of $98.24.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. The business had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, analysts forecast that iRadimed will post 1.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on IRMD shares. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Lake Street Capital reiterated a “buy” rating and set a $100.00 target price on shares of iRadimed in a research report on Monday, November 3rd. Roth Capital set a $90.00 price target on iRadimed in a report on Friday, October 31st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research note on Thursday. Finally, Zacks Research raised shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $87.33.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.